Microbix Biosystems (TSE:MBX) Director Martin Marino Purchases 115,000 Shares of Stock

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino acquired 115,000 shares of Microbix Biosystems stock in a transaction on Thursday, May 28th. The stock was purchased at an average price of C$0.28 per share, with a total value of C$32,200.00. Following the transaction, the director directly owned 2,000,167 shares in the company, valued at approximately C$560,046.76. This trade represents a 6.10% increase in their position.

Martin Marino also recently made the following trade(s):

• On Tuesday, May 26th, Martin Marino acquired 69,000 shares of Microbix Biosystems stock. The stock was purchased at an average price of C$0.26 per share, with a total value of C$17,940.00.
• On Wednesday, May 27th, Martin Marino acquired 24,500 shares of Microbix Biosystems stock. The stock was purchased at an average price of C$0.26 per share, with a total value of C$6,370.00.

Microbix Biosystems Price Performance

Shares of MBX stock opened at C$0.28 on Friday. The stock has a 50 day moving average of C$0.24 and a two-hundred day moving average of C$0.24. The company has a current ratio of 5.35, a quick ratio of 5.57 and a debt-to-equity ratio of 27.03. Microbix Biosystems Inc. has a 12 month low of C$0.21 and a 12 month high of C$0.34. The company has a market capitalization of C$37.81 million, a P/E ratio of -6.71 and a beta of 0.48.

Microbix Biosystems (TSE:MBX) last announced its quarterly earnings data on Thursday, May 14th. The company reported C($0.01) EPS for the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%.The firm had revenue of C$3.38 million during the quarter. As a group, equities analysts expect that Microbix Biosystems Inc. will post 0.02 EPS for the current year.

Microbix Biosystems Company Profile

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.